MedTrace Logo

Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC

NCT03045393 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2018-07-05

No results posted yet for this study

Summary

The main purpose of this study is to determine how 2 doses mirvetuximab soravtansine affects the amount and activity of folate receptor alpha proteins in tumor cells of patients who have completed standard neoadjuvant treatment and are scheduled to have their tumors surgically removed.

Conditions

  • Breast Cancer Triple Negative

Interventions

DRUG

Mirvetuximab Soravtansine (IMGN853)

Mirvetuximab Soravtansine is a targeted drug for tumors that express high levels of folate receptor alpha.

Sponsors & Collaborators

Principal Investigators

  • Kimberly Blackwell, MD · Duke University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-17
Primary Completion
2018-02-28
Completion
2018-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03045393 on ClinicalTrials.gov